 |
|
 |
| Results of MOCA Funded Research |
S100A1 Expression in Ovarian and Endometrial Endometrioid Carcinomas Is a Prognostic Indicator of Relapse-Free Survival
Melissa S. DeRycke, MS, John D. Andersen, Katherine M. Harrington, Stefan E. Pambuccian, MD, Steve E. Kalloger, Kristin L.M. Boylan, PhD, Peter A. Argenta, MD, and Amy P.N. Skubitz, PhD
American Journal of Clinical Pathology, 2009;132:846-856
Differential gene expression identifies subgroups of ovarian carcinoma
Amy P.N. Skubitz, Ph.d, Stefan E. Pambuccian, MD, Peter A. Argenta, MD, and Keith M. Skubitz, MD
Translational Research
Volume 148, Number 5; 223-249; April 2006
Disaggregation and invasion of ovarian carcinoma ascites spheroids
Kathryn M Burleson, Matthew P Boente, Stefan E Pambuccian and Amy PN Skubitz
Journal of Translational Medicine, 4:6; Jan. 24, 2006
Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers
Kathryn M. Burleson, Linda K. Hansen & Amy P.N. Skubitz
Clinical & Experimental Metastasis (2004) 21: 685–697
Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers
Kathryn M. Burleson, Rachael C. Casey, Keith M. Skubitz, Stephan E. Pambuccian, Theodore R. Oegema Jr., and Amy P.N. Skubitz
Gynecologic Oncology 93 (2004) 170–181
Differential Gene Expression in Ovarian Carcinoma
Kathleen Hibbs, Keith M. Skubitz, Stefan E. Pambuccian, Rachael C. Casey, Kathryn M. Burleson, Theodore R. Oegema Jr., Jeannine J. Thiele, Suzanne M. Grindle, Robin L. Bliss, and Amy P.N. Skubitz
American Journal of Pathology, Vol. 165, No. 2, August 2004, 397-414
PEER REVIEWED MANUSCRIPTS
“Centering Prayer for Women Receiving Chemotherapy for Recurrent Ovarian Cancer: A Pilot Study”, Oncology Nursing Forum.
“Regulation of HSulf-1 expression by variant hepatic nuclear
factor 1 in ovarian cancer.”
Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V.
Cancer Res. 2009 Jun 1;69(11):4843-50.
“Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis”
John D. Andersen, Kristin L. M. Boylan, Feifei S. Xue, Lorraine B. Anderson, Bruce A. Witthuhn, Todd W. Markowski, LeeAnn Higgins, Amy P. N. Skubitz
Electrophoresis 2010, 31, 599–610
“Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum”
Kristin L.M. Boylan, John D. Andersen, Lorraine B. Anderson, LeeAnn Higgins, and Amy P.N. Skubitz
“Leucine-rich alpha-2-glycoprotein-1 is Upregulated in Sera and Tumors of Ovarian Cancer Patients”
John D. Andersen, Ronald Jemmerson, Melissa A. Geller, Benjamin Misemer, Kristin L.M. Boylan, Katherine M. Harrington, Starchild Weivoda, Bruce A. Witthuhn, Peter Argenta, Rachel Isaksson Vogel5 and Amy P.N. Skubitz
“Nectin 4 overexpression in ovarian cancer tissues and sera: Potential role as a serum biomarker”
Melissa S. DeRycke, Stefan E. Pambuccian, C. Blake Gilks, Steve E. Kalloger, Abderrezak Ghidouche, Marc Lopez, Robin L. Bliss, Melissa A. Geller, Peter A. Argenta, Kathryn M.Harrington, and Amy P.N. Skubitz
American Journal of Clinical Pathology
|
|
 |
